Amy Baxter

1 week ago | pharmavoice.com | Amy Baxter

This audio is auto-generated. Please let us know if you have feedback. When Novartis announced it was teaming up with the NFL last month, the company called it the first-ever corporate pharmaceutical partnership with the league. But it wasn’t exactly the only matchup between the industry and the professional football world. The NFL has inked several deals with pharma companies, starting with a 2003 sponsorship agreement that co-promoted a Bayer and GSK drug that was under FDA review.

1 week ago | pharmavoice.com | Amy Baxter

This audio is auto-generated. Please let us know if you have feedback. Stock market whiplash is dampening hopes for a comeback year in the biotech arena. Roughly 25% of biotech stock values sank below their cash holdings last week amid sudden changes to U.S. trade policy, Bloomberg reported. In an economic situation that’s shifting by the day, “the only thing that's certain is uncertainty,” said David Crean, managing partner at M&A consulting firm Cardiff Advisory.

2 weeks ago | pharmavoice.com | Amy Baxter

This audio is auto-generated. Please let us know if you have feedback. With $16.9 billion in sales in 2024 alone, Novo Nordisk has clearly received huge R&D returns from its blockbuster obesity and diabetes drugs Ozempic and Wegovy. And it’s not alone among companies cashing in. R&D returns for 2024 rose to 5.9% for the top 20 biopharma companies, up from about 4% the year before and continuing a year-over-year upward climb, according to forecasts in a new Deloitte report.

2 weeks ago | pharmavoice.com | Amy Baxter

This audio is auto-generated. Please let us know if you have feedback. When an Alzheimer’s drug recently gained a second chance from European regulators after an initial rejection, the decision bucked the agency’s norm. Leqembi became the first fully FDA-approved drug among the emerging class of anti-amyloid Alzheimer’s treatments in 2023. Developed by Biogen and Eisai, Leqembi was originally granted an accelerated approval by the FDA before scoring a full nod later in the year.

3 weeks ago | pharmavoice.com | Meagan Parrish |Amy Baxter

This audio is auto-generated. Please let us know if you have feedback. A massive round of job cuts hit HHS this week, impacting a wide range of staffers of all rank and file. And more details about who exactly got the boot are starting to emerge. An entire team devoted to FDA communications was among the 3,500 agency employees who were fired on Tuesday, NPR reported.